ACRIVON THERAPEUTICS INC (ACRV)
US0048901096 - Common Stock
ACRIVON THERAPEUTICS INC
NASDAQ:ACRV (5/3/2024, 7:00:00 PM)
After market: 9.59 0 (0%)9.59
+1.13 (+13.36%)
Company Profile
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2022-11-15. The firm uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead clinical candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency. ACR-368 is in Phase II trial across multiple solid tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy, which improves the clinical overall response rate (ORR), and has the potential to enable expedited drug development. The firm is also developing two preclinical drug programs, such as WEE1 inhibitors and PKMYT1 inhibitor.
Company Info
ACRIVON THERAPEUTICS INC
480 Arsenal Way, Suite 100
Watertown MASSACHUSETTS
P: 16172078979
Employees: 56
Website: https://acrivon.com/
ACRV News
10 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning!
11 days ago - ChartmillGet insights into the top gainers and losers of Wednesday's after-hours session.Get insights into the top gainers and losers of Wednesday's after-hours session.
11 days ago - Acrivon Therapeutics, IncAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative)...
18 days ago - Acrivon Therapeutics, IncAcrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-231625 days ago - Acrivon Therapeutics, IncAcrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of ActionableACRV Twits
Here you can normally see the latest stock twits on ACRV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
